July 21, 2022
The Ministry of Health, Labor and Welfare (MHLW) on July 20 ordered label revisions for a batch of drugs including the addition of encephalitis risks for AstraZeneca’s Imfinzi (durvalumab) and Merck Biopharma’s Bavencio (avelumab), both PD-L1 inhibitors. In the updated...read more